However, the National Cancer Institute (NCI)'s Physician Data Query (PDQ) summarized the cancer information about CML-CP treatment and reported that, in a retrospective analysis, even the patients with BCR/ABL1 transcript level greater than 10% after 3 months of therapy did well when the halving time was less than 76 days (all patients enrolled in Australia, New Zealand, Singapore, South Africa, and South America)12, and mandating a change of therapy based on this 10% transcript level at 3 to 6 months was problematic because 75% of patients did well even with a suboptimal response1. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.